Word: wondered
(lookup in dictionary)
(lookup stats)
Dates: during 1990-1999
Sort By: most recent first
(reverse)
...awards and brought crowds of all colors to the theater. Two years later, the show is on its first national tour, and is currently experiencing its first-ever performance run in Boston. Although many of the cast members were plucked straight from the Broadway version, one cannot help but wonder if a tour production of Noise/Funk will live up to the reputation that the original has created. Can such a physically and emotionally taxing show perform day after day, in city after city, and still pulse with the energy that brought people to their feet cheering in New York...
...find a way to convey the massiveness of the library. And as her shot pans through my body, it strikes me that I've played supporting roles in literally dozens of these Cambridge video diaries. Just how many home movies, how many photo albums have I stumbled into, I wonder...
...wonder the last line of the DOJ's lawsuit against Microsoft asks "that the plaintiff recover the costs of this action" -- in other words, that Bill Gates cough up for Klein's legal fees. But the AAG's point is well taken: When billion-dollar corporate lovefests like Travelers Group-Citicorp and Daimler Benz-Chrysler seem to take place every other day, and the responsible watchdog's budget has not been adjusted for inflation since 1993, it's time to pass the hat. Still, as anyone who has tried to navigate www.usdoj.gov/atr knows, the first thing Klein needs...
...risks are especially acute in the complex world of biotechnology, where each of some 300 public companies, including EntreMed, claims to have one or more wonder drugs in research. Those claims make terrific investment pitches, and on the heels of a successful new drug launch--Pfizer's impotence pill, Viagra, in this case--investors can get, uh, excited. The reality, though, is that maybe 10% of today's biotech companies will ever bring a blockbuster drug to the market. Those that do will enrich shareholders. But casual investors face long odds trying to be in the right stocks...
That said, there are reasons to invest in the wonder-drug business. A potential huge payoff certainly is one. Last July, MedImmune's infant-pneumonia drug, Synagis, passed a significant clinical hurdle, and the stock shot from $15 to $55. More fundamentally, though, biotech stocks as a group have been woeful laggards for three years, and may represent the broadest base of value in today's sky-high stock market...